HIGHLIGHTS
- who: PTPRD-mutation and collaborators from the Chinese Academy of Medical Sciences Shuguang Hospital, Shanghai University Pathology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China have published the article: Case Report: Clinical complete response of advanced renal cell carcinoma associated with Xp11.2 translocation/TFE3 gene fusion by treated by camrelizumab and axitinib: A rare case report, in the Journal: (JOURNAL)
- future: Due to the poor prognosis in adult Xp11.2 tRCC more research is needed to evaluate the effects of postoperative adjuvant therapy.
SUMMARY
Surgical resection achieved . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.